Peter A Kouides

List of Publications by Year
in descending order

112	2,403	201385 27	243296 44
papers	citations	h-index	g-index

118	118	118	1772
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Obstetric and gynaecological aspects of von Willebrand disease. Best Practice and Research in Clinical Haematology, 2001, 14, 381-399.	0.7	217
2	Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion, 2014, 54, 1756-1768.	0.8	167
3	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	2.5	152
4	Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood, 2015, 126, 2038-2046.	0.6	126
5	Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. British Journal of Haematology, 2009, 145, 212-220.	1.2	117
6	Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 124-134.	0.5	108
7	Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertility and Sterility, 2005, 84, 1345-1351.	0.5	81
8	A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 1883-1887.	1.9	59
9	Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertility and Sterility, 2005, 84, 1338-1344.	0.5	53
10	Management of excessive menstrual bleeding in women with hemostatic disorders. Fertility and Sterility, 2005, 84, 1352-1359.	0.5	51
11	Systemic Mastocytosis: A Concise Clinical and Laboratory Review. Archives of Pathology and Laboratory Medicine, 2007, 131, 784-791.	1.2	49
12	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leukemia and Lymphoma, 2007, 48, 1410-1413.	0.6	48
13	Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment. Current Cardiology Reports, 2020, 22, 52.	1.3	47
14	Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation and Fibrinolysis, 2015, 26, 383-388.	0.5	46
15	Cytarabine-induced pericarditis: A case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leukemia Research, 1995, 19, 141-144.	0.4	45
16	Rituximab-Induced Leukocytoclastic Vasculitis: A Case Report. Archives of Dermatology, 2006, 142, 246.	1.7	43
17	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	2.5	43
18	Regional variation and cost implications of prescribed extended halfâ€life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia, 2019, 25, 668-675.	1.0	38

#	Article	IF	Citations
19	Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Advances, 2019, 3, 2381-2387.	2.5	38
20	Understanding the Myelodysplastic Syndromes. Oncologist, 1997, 2, 389-401.	1.9	38
21	Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: Case report and review of the literature of lymphoblastic transformation of myelodysplastic syndrome. American Journal of Hematology, 1995, 49, 157-162.	2.0	37
22	Allergic reactions to cyclophosphamide: Delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. Journal of Allergy and Clinical Immunology, 1996, 97, 26-33.	1.5	37
23	Bleeding disorders in adolescents with heavy menstrual bleeding in a multicenter prospective US cohort. Haematologica, 2020, 105, 1969-1976.	1.7	37
24	A Benefit-Risk Review of Systemic Haemostatic Agents. Drug Safety, 2008, 31, 275-282.	1.4	33
25	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	1.0	32
26	A Benefit-Risk Review of Systemic Haemostatic Agents. Drug Safety, 2008, 31, 217-230.	1.4	29
27	Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. Blood Reviews, 2019, 38, 100572.	2.8	29
28	von Willebrand Disease in the Pediatric and Adolescent Population. Journal of Pediatric and Adolescent Gynecology, 2010, 23, S3-S10.	0.3	28
29	Large granular lymphocyte leukemia presenting with both amegakaryocytic thrombocytopenic purpura and pure red cell aplasia: Clinical course and response to immunosuppressive therapy. American Journal of Hematology, 1995, 49, 232-236.	2.0	27
30	Metachronous Development of Nonamyloidogenic Î» Light Chain Deposition Disease and IgG Heavy Chain Amyloidosis in the Same Patient. American Journal of Surgical Pathology, 2003, 27, 1477-1482.	2.1	26
31	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARSâ€CoVâ€2 infection. Journal of Thrombosis and Haemostasis, 2020, 18, 2640-2645.	1.9	26
32	Hematologic neoplasia and the central nervous system. , 1999, 62, 234-238.		23
33	The scope and value of an anticoagulation stewardship program at a community teaching hospital. Journal of Thrombosis and Thrombolysis, 2017, 43, 380-386.	1.0	22
34	Aspects of the Laboratory Identification of von Willebrand Disease in Women. Seminars in Thrombosis and Hemostasis, 2006, 32, 480-484.	1.5	21
35	Prospective evaluation of ISTHâ€BAT as a predictor of bleeding disorder in adolescents presenting with heavy menstrual bleeding in a multidisciplinary hematology clinic. Journal of Thrombosis and Haemostasis, 2020, 18, 2542-2550.	1.9	21
36	Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: A case report of bilateral uterine artery embolization. American Journal of Hematology, 2004, 77, 151-155.	2.0	20

#	Article	IF	Citations
37	The impact of extended halfâ€life factor concentrates on prophylaxis for severe hemophilia in the United States. American Journal of Hematology, 2020, 95, 960-965.	2.0	19
38	Flutamideâ€induced cyanosis refractory to methylene blue therapy. British Journal of Haematology, 1996, 94, 73-75.	1.2	18
39	PNEUMOCYSTIS CARINII PNEUMONIA AS A COMPLICATION OF DESFERRIOXAMINE THERAPY. British Journal of Haematology, 1988, 70, 383-384.	1.2	17
40	Bleeding symptom assessment and hemostasis evaluation of menorrhagia. Current Opinion in Hematology, 2008, 15, 465-472.	1.2	17
41	Outgrowing the laboratory diagnosis of type 1 von <scp>W</scp>illebrand disease: A two decade study. American Journal of Hematology, 2018, 93, 232-237.	2.0	17
42	The spectrum and severity of bleeding in adolescents with low von Willebrand factorâ€“associated heavy menstrual bleeding. Blood Advances, 2020, 4, 3209-3216.	2.5	17
43	Laboratory misdiagnosis of von Willebrand disease in <scp>postâ€menarchal</scp> females: A <scp>multiâ€center</scp> study. American Journal of Hematology, 2020, 95, 1022-1029.	2.0	15
44	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Advances, 2022, 6, 228-237.	2.5	15
45	Pseudoleukemia following the use of G-CSF. American Journal of Hematology, 1995, 49, 258-259.	2.0	14
46	A Morphometric Analysis of Platelet Dense Granules of Patients with Unexplained Bleeding: A New Entity of Delta-Microgranular Storage Pool Deficiency. Journal of Clinical Medicine, 2020, 9, 1734.	1.0	14
47	VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naiˆve Multiple Myeloma (MM).. Blood, 2004, 104, 3463-3463.	0.6	14
48	An update on the management of bleeding disorders during pregnancy. Current Opinion in Hematology, 2015, 22, 397-405.	1.2	13
49	Safety of a pasteurized plasmaâ€derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data. Transfusion, 2017, 57, 2390-2403.	0.8	13
50	Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2021, 27, 445-453.	1.0	13
51	Platelet function testing: state of the art. Expert Review of Cardiovascular Therapy, 2007, 5, 955-967.	0.6	12
52	Features of Electronic Health Records Necessary for the Delivery of Optimized Anticoagulant Therapy. Annals of Pharmacotherapy, 2015, 49, 113-124.	0.9	12
53	A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Leukemia Research, 1995, 19, 763-770.	0.4	11
54	Pathology of Thrombotic Thrombocytopenic Purpura in the Placenta, with Emphasis on the â€œSnowman Signâ€. Pediatric and Developmental Pathology, 2007, 10, 455-462.	0.5	11

#	Article	IF	Citations
55	Validation Study of the Composite Score to Identify Von Willebrand Disease in Children. Journal of Pediatric Hematology/Oncology, 2016, 38, 139-142.	0.3	11
56	Feasibility of the Von Willebrand disease PREVENT trial. Thrombosis Research, 2017, 156, 8-13.	0.8	9
57	Effectiveness of intravenous immunoglobulin use in heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 2020, 31, 287-292.	0.5	8
58	Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations. Blood Advances, 2017, 1, 699-702.	2.5	7
59	Examining international practices in the management of pregnant women with von Willebrand disease. Journal of Thrombosis and Haemostasis, 2022, 20, 82-91.	1.9	7
60	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Advances, 2022, 6, 121-128.	2.5	7
61	Evaluation of abnormal bleeding in women. Psychophysiology, 2002, 1, 11-8.	1.1	6
62	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	2.5	5
63	Outcomes of longâ€term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. Haemophilia, 2022, 28, 373-387.	1.0	5
64	Efficacy and safety of halfâ€dose desmopressin for bleeding prophylaxis in bleeding disorder patients undergoing predominantly low to moderate risk invasive procedures. American Journal of Hematology, 2020, 95, E285.	2.0	4
65	A Multi-Site, Prospective Cross-Over Study of Intranasal Desmopressin and Oral Tranexamic Acid in Women with Menorrhagia and Abnormal Laboratory Hemostasis.. Blood, 2007, 110, 711-711.	0.6	4
66	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2014, 124, 2836-2836.	0.6	4
67	Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Advances, 2022, 6, 420-428.	2.5	4
68	Safe and Effective Use of Chronic Transdermal Estradiol for Life-Threatening Uremic Bleeding in a Patient with Coronary Artery Disease. Nephron Extra, 2014, 4, 134-137.	1.1	3
69	North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. Journal of Women's Health, 2021, 30, 829-836.	1.5	3
70	Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis. Cureus, 2021, 13, e14572.	0.2	3
71	Cardiac ALL: Most Unusual Occurrence of Lenalidomide-associated Acute Lymphoblastic Leukemia with Subsequent Cardiac Involvement. Cureus, 2019, 11, e6009.	0.2	3
72	Antenatal Diagnosis. , 0, , 99-123.		2

#	Article	IF	Citations
73	Von Willebrand Disease and other Disorders of Hemostasis in the Patient with Menorrhagia. Women's Health, 2005, 1, 231-244.	0.7	2
74	Genetic and Laboratory Diagnosis. , 0, , 90-98.		2
75	Obstetric Management. , 0, , 124-150.		2
76	A Threshold Optical Density Value In Immunoassay Predicts Thrombosis In Patients with Heparin Induced Thrombocytopenia. Blood, 2013, 122, 4755-4755.	0.6	2
77	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2015, 126, 761-761.	0.6	2
78	Design of the Von Willebrand Factor in Pregnancy (VIP) Study. Blood, 2020, 136, 29-29.	0.6	2
79	Does a Bleeding Disorder Lessen the Efficacy of the 52-mg Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding in Adolescents? A Retrospective Multicenter Study. Journal of Adolescent Health, 2022, 71, 204-209.	1.2	2
80	Diagnosis and management of heparin-induced thrombocytopenia. Expert Review of Cardiovascular Therapy, 2005, 3, 335-345.	0.6	1
81	Advocacy for Women with Bleeding Disorders. , 0, , 176-183.		1
82	Analgesia and Anesthesia for Pregnant Women with Inherited Bleeding Disorders. , 0, , 151-162.		1
83	Appendix i: Bleeding Score with Assigned Score for Each Bleeding Symptom. , 0, , 184-185.		1
84	Approach to the Patient with an Inherited Bleeding Disorder. , 0, , 1-11.		1
85	A presumed case of Darbepoetinâ€induced myocardial infarction in the patient with MDSâ€RARS. Clinical Case Reports (discontinued), 2020, 8, 658-660.	0.2	1
86	Low von Willebrand Factor in Children and Adolescents. JAMA Pediatrics, 2021, 175, 1060-1067.	3.3	1
87	Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVIDâ€19 infection. Haemophilia, 2021, 27, e517-e519.	1.0	1
88	The Prevalence and Impact of Arrhythmias in Hospitalized Patients with Sickle Cell Disorders: A Large Database Analysis. Blood, 2020, 136, 5-6.	0.6	1
89	Females with Severe or Moderate Hemophilia A or B: A U.S. Study.. Blood, 2007, 110, 2146-2146.	0.6	1
90	Effect of SSRI Use On Platelet Function Testing and Bleeding Symptoms.. Blood, 2009, 114, 3508-3508.	0.6	1

#	Article	IF	Citations
91	ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN). Blood, 2021, 138, 3637-3637.	0.6	1
92	Infections affecting blood cell morphology. , 1998, 59, 238-241.		0
93	Viral Safety of Plasma Products. Laboratory Medicine, 2003, 34, 667-671.	0.8	0
94	Rare Bleeding Disorders. , 0, , 54-64.		0
95	Appendix ii: Pictorial Blood Assessment Chart. , 0, , 186-187.		0
96	The newborn. , 0, , 163-175.		0
97	Physiology of Menstruation and Menorrhagia. , 0, , 12-33.		0
98	von Willebrand Disease. , 0, , 42-53.		0
99	Hemophilia A and Hemophilia B. , 0, , 34-41.		0
100	Rare case of hemolytic uremic syndrome associated with only one transient low platelet count. Journal of Hematopathology, 2012, 5, 325-327.	0.2	0
101	The Variable Success of Managing Bleeding Disorder Related Menorrhagia: A Multicenter Study within the Hemophilia Treatment Center Network.. Blood, 2004, 104, 3089-3089.	0.6	0
102	Predictors of Von Willebrand Disease In Children: A Case-Control Study. Blood, 2010, 116, 712-712.	0.6	0
103	Validation Study Of The Composite Score To Identify Von Willebrand Disease in Children. Blood, 2013, 122, 2356-2356.	0.6	0
104	Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease. Blood, 2015, 126, 2293-2293.	0.6	0
105	Association of Obesity on Laboratory Profiles of Individuals with Type 1 Von Willebrand Disease and Low VWF in the Athn Dataset. Blood, 2019, 134, 2415-2415.	0.6	0
106	Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions. Blood, 2019, 134, 1120-1120.	0.6	0
107	Bleeding Disorders in Pregnancy. , 2020, , 319-322.		0
108	The Von Willebrand Disease Aging and Bleeding Correlation (VWD ABC) Study. Blood, 2021, 138, 1044-1044.	0.6	0

#	Article	IF	Citations
109	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. Blood, 2020, 136, 29-29.	0.6	0
110	The Certainty of a Post-Bone Marrow Diagnosis: A Study of the Yield of Bone Marrow Biopsies in a Community Hospital Setting. Blood, 2020, 136, 34-35.	0.6	0
111	All catastrophes are not catastrophic antiphospholipid syndrome. American Journal of Hematology, 2022, 97, 968-974.	2.0	0
112	Impact of obesity on factor VIII and von Willebrand factor levels in patients with Type 1 von Willebrand disease and low von Willebrand factor: An analysis of the ATHNdataset. Haemophilia, 2022, 28, 109-116.	1.0	0